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http:WHAT THIS PAPER ADDS
The need for a large-scale randomized trial comparing CEA versus CAS: A Cochrane meta-analysis of CEA versus
CAS trials (mainly in symptomatic patients) states “There is a strong case to continue recruitment in current
randomized trials comparing carotid stenting with endarterectomy”. Multicentre large clinical trials are partic-
ularly needed in asymptomatic patients and the European Stroke Initiative suggests stenting be considered only
within randomized trials. The UK National Institute for Clinical Excellence (NICE) recently (April, 2011) also
recommended stenting for asymptomatic carotid stenosis be carried out within the ACST-2 trial.Objectives: ACST-2 is currently the largest trial ever conducted to compare carotid artery stenting (CAS) with
carotid endarterectomy (CEA) in patients with severe asymptomatic carotid stenosis requiring revascularization.
Methods: Patients are entered into ACST-2 when revascularization is felt to be clearly indicated, when CEA and
CAS are both possible, but where there is substantial uncertainty as to which is most appropriate. Trial surgeons
and interventionalists are expected to use their usual techniques and CE-approved devices. We report baseline
characteristics and blinded combined interim results for 30-day mortality and major morbidity for 986 patients in
the ongoing trial up to September 2012.
Results: A total of 986 patients (687 men, 299 women), mean age 68.7 years (SD  8.1) were randomized equally
to CEA or CAS. Most (96%) had ipsilateral stenosis of 70e99% (median 80%) with contralateral stenoses of 50e
99% in 30% and contralateral occlusion in 8%. Patients were on appropriate medical treatment. For 691 patients
undergoing intervention with at least 1-month follow-up and Rankin scoring at 6 months for any stroke, the
overall serious cardiovascular event rate of periprocedural (within 30 days) disabling stroke, fatal myocardial
infarction, and death at 30 days was 1.0%.
Conclusions: Early ACST-2 results suggest contemporary carotid intervention for asymptomatic stenosis has a low
risk of serious morbidity and mortality, on par with other recent trials. The trial continues to recruit, to monitor
periprocedural events and all types of stroke, aiming to randomize up to 5,000 patients to determine any
differential outcomes between interventions.
Clinical trial: ISRCTN21144362.
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ACST-1 (1993e2003) was a trial of carotid endarterectomy
(CEA) versus no immediate procedure and demonstrated
the effectiveness of CEA over deferred surgery in stroke
prevention.1,2 Asymptomatic surgery has a generally low
procedural hazard and, in the more recent Carotid Revas-
cularization Endarterectomy vs. Stent Trial (CREST),3 the 30-
day stroke and death rate for asymptomatic patients was
1.4% (CEA) and 2.5% (CAS), comparing favourably with
ACST-1, where the hazard for surgery alone was 3%.responding author. A. Halliday, Nuffield Department of Surgery, John Ra
il address: alison.halliday@nds.ox.ac.uk
-5884/$ e see front matter  2013 European Society for Vascular Surg
//dx.doi.org/10.1016/j.ejvs.2013.07.020Improved medical treatment, especially with statins, newer
surgical and interventional techniques, and the generalized
use of cerebral protection devices together with greater
experience and refinement of patient selection may influ-
ence outcomes in carotid intervention.
With the current availability of carotid artery stenting
(CAS), if a patient is determined to need an intervention for
asymptomatic carotid stenosis, there may be continued
substantial uncertainty whether to opt for CEA or CAS based
on the limited data currently available. ACST-2 seeks todcliffe Hospital, University of Oxford.
ery. Published by Elsevier Ltd. All rights reserved.
ACST-2 Collaborative Group 511randomize 5,000 such individuals between CEA and CAS to
compare both the immediate hazards of the two pro-
cedures when done by experienced doctors and the sub-
sequent stroke rates over the next 5e10 years. In an effort
to assure completion of such a large and important trial, the
workload per patient in this trial has been minimized, so
that the study can be integrated easily into routine
healthcare.4MATERIALS AND METHODS
Trial treatments
Patients are randomized in a 1:1 fashion, and all are to be
followed up for at least 5 years (mainly by mail) and ana-
lysed on an intention-to-treat basis. The eligibility is based
on physician uncertainty as to the specific treatment after
the decision to treat has been made, and it is intended to
ensure large-scale recruitment of an appropriately hetero-
geneous and representative group. This increases the
medical value of the study, perhaps making it possible to
determine whether the net effects of CEA/CAS are influ-
enced by certain patient characteristics recorded at entry.
The primary objectives of the trial are to compare on an
intention-to-treat basis 1) periprocedural risks (myocardial
infarction [MI], stroke and death within the first month
after the allocated CEA or CAS is attempted by an experi-
enced practitioner), and 2) long-term (up to 5 or more
years) prevention of stroke, particularly disabling or fatal
stroke, in subsequent years.
Secondary objectives include data analysis in order to
assess whether some types of patients can be identified in
which one or other procedure is clearly preferable. As part
of a health economic evaluation, procedural costs and
stroke-related healthcare costs and quality of life will be
assessed.Patient entry into ACST-2
Each centre must have a collaborating neurologist (or stroke
physician), vascular surgeon, and stenting interventionalist.
They are jointly responsible for patient recruitment, treat-
ment, and follow-up. The stenting interventionalist can be
a radiologist, cardiologist, surgeon, or physician with
specialist training in carotid stenting. A “centre” can be
organized between colleagues in neighbouring hospitals,
making a so-called “hub-and-spoke” arrangement.
Vascular surgeons who may perform CEA in the trial
should already have had a reasonable amount of successful
experience with the procedure. Likewise, interventionalists
who may perform CAS in the trial should already have had a
reasonable amount of experience with up-to-date tech-
niques of stenting.
The experience of surgeons and interventionalists is
vetted through the study management committees.
Suitable patients are those with carotid artery stenosis
detectable by duplex ultrasound, with no ipsilateral carotid
territory symptoms (or none for at least 6 months) and no
previous ipsilateral carotid procedure, who are thoughtlikely to benefit from procedural treatment with CEA or
CAS. Patients should already have been started on any
appropriate medical treatment (e.g. statin, aspirin, diabetes
management, and blood pressure-lowering medication),
and should have recovered from any necessary coronary
procedures (e.g. coronary artery bypass graft). All patients
for the trial should be eligible for both CEA and CAS without
excessive risk, have an expected lifespan of at least 5 years,
and willing to be followed-up in person (at 1 month) and by
annual letter (for at least 5 years). Some type of cross-
sectional imaging (e.g. magnetic resonance angiography or
computed tomography angiography) must already have
been done which has shown that CEA and CAS would both
be anatomically practicable.
The doctor and the patient should both, after a full dis-
cussion about the hazards and benefits of both in-
terventions, be substantially uncertain about whether to
treat with CEA or CAS. Patients should not be included
where there is a small likelihood of worthwhile benefit (e.g.
very low risk of stroke because stenosis is not severe, or
major comorbidity or life-threatening disease, such as
advanced cancer, which would be expected to limit life-
span), or where the patient is unsuitable for one or
other procedure (e.g. stenosis at carotid siphon that is
inaccessible for CEA, or complex vasculature below the
stenosis that would hinder CAS, or if the patient is unfit for
major surgery). Once these considerations have been
completed, the Randomization (ESM Fig. 1) and Consent
forms are completed and the patient can be randomized
into ACST-2.
The CEA or CAS should then be done as soon as possible
(ideally within the first month after randomisation) by a
collaborator whose track record for that procedure has
been approved. It is the responsibility of this collaborator to
use techniques and equipment that are appropriate for
routine clinical practice (e.g. in Europe, CE-marked stents).
Cerebral protection devices are optional (i.e. at the collab-
orator’s discretion), but encouraged.
Before discharge, collaborators are advised to schedule a
Duplex ultrasound and a 1-month clinical follow-up visit and
schedule assessment by a neurologist/stroke physician
(within 1 month of the procedure) of whether or not the
patient had a periprocedural stroke or MI.
All other care remains the responsibility of the patient’s
doctor, and not the trial. Patients do not need to undergo
any other tests or examinations beyond those provided as
part of their routine care. The 1-month post-procedural
form (ESM Fig. 2) has then to be completed and sent to
the ACST office.Longer-term follow-up
Annual follow-up for at least 5 years (to monitor any
strokes) will usually be by the ACST office writing to the
patient. After the 1-month post-procedural form, no further
follow-up by the doctor is required (unless fuller details of a
self-reported stroke need to be provided). Patients will be
contacted annually for at least 5 years by a letter originating
Figure 1. Current therapy at 1-month follow-up. Blue ¼ carotid
endarterectomy; red ¼ carotid artery stenting.
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well, and enclosing a brief questionnaire. Both will be in the
patient’s own language, with a prepaid envelope for return
to an ACST office.Data Monitoring Committee
During the study, interim analyses of major events are being
supplied at least annually to an independent Data Moni-
toring Committee (DMC).
The DMC will advise the Trial Steering Committee (TSC) if
there is an unacceptably high morbidity associated with CEA
or CAS (either overall, or in particular centres, or in the
centres with more limited prior experience), or if there is
clear evidence that, for all patients or some particular types
of patient, there is proof beyond reasonable doubt that one
or the other procedure is preferable. Until then, the TSC and
collaborators will otherwise remain unaware of interim
unblinded results.Figure 2. Stents used. Blue ¼ straight stents used; red ¼ tapered
stents used.Appropriate criteria of proof beyond reasonable doubt
cannot be specified precisely, but a difference of at least
three standard deviations in an interim analysis of a major
endpoint may be needed to justify halting or modifying
such a study prematurely.
Major periprocedural events
Strokes (within the first post-procedural month or during
long-term postal follow-up). Stroke severity is classified by
outcome using the modified Rankin disability scale after 6
months have elapsed since the event:
0 No symptoms at all from the stroke.
1 No significant disability, despite any symptoms from the
stroke: able to carry out usual activities.
2 Slight disability because of the stroke: unable to carry
out all previous activities but able to look after their
own affairs without assistance.
3 Moderate disability from the stroke: requiring some
help, but able to walk without assistance.
4 Moderately severe disability from the stroke: unable to
walk without assistance and unable to attend to their
own bodily needs without assistance.
5 Severe disability from it: bedridden, incontinent, and
requiring constant nursing care and attention.
6 Died directly or indirectly from the stroke.
Peri- or post-procedural myocardial infarction (within the
first month)
It is necessary to report MI only if this occurs during the
peri- or post-procedural (1 month) period. Routine post-
procedure ECG and enzyme determination are not
required. If more than one MI occurs in this month, each
should be reported. A definite diagnosis of MI can be
made only if at least two of the following criteria are
fulfilled:
1 Symptoms consistent with MI.
2 Positive enzyme or biomarker (e.g. troponin-T) changes
consistent with MI.
3 ECG changes consistent with MI.
Death
If the patient dies within 1 month of the trial procedure
(CEA/CAS), the cause and circumstances are to be described
on the 1-month post-procedural form. Otherwise, follow-up
is by mail from the ACST office, with later deaths reported
by patients’ relatives via annual questionnaires.
Statistical analysis
The main trial outcomes will be MI, stroke, or death 1
month after the allocated procedure (CEA or CAS), and
long-term (up to 5 or more years) stroke rates. With 5,000
randomized patients, a decrease of about 60% in the per-
iprocedural myocardial infarction rate with stenting versus
surgery (e.g. 2% CEA vs. 0.8% CAS) and an increase of
about 60% in the 5-year stroke rate (e.g. 3% CEA vs. 5%
Table 1. ACST-2 baseline characteristics.
Total
n ¼ 986 (%)
Age at entry
Mean  SD (yrs) 68.7  8.1
<65 241 (24.4)
65e74 401 (40.7)
75 344 (34.9)
Sex
Men 687 (69.7)
Women 299 (30.3)
Pre-randomization SBP (mean)
<160 mmHg 888 (90.1)
160 mmHg 98 (9.9)
Plaque echolucency (% soft)
<25 309 (31.3)
25 256 (26.0)
Not estimated 421 (42.7)
Risk factors recorded at entry
Atrial fibrillation 55 (5.6)
Coronary artery disease 364 (36.9)
Diabetes 298 (30.2)
Renal impairment 106 (10.7)
Medication use at randomization
Antiplatelet 814 (82.6)
Anticoagulant 65 (6.0)
Antihypertension 778 (78.9)
Lipid lowering 736 (74.6)
Stenosis at randomization (%)
Ipsilateral diameter reduction
0e49% 0 (0.0)
50e69% 39 (4.0)
70e99% 947 (96.0)
Contralateral diameter reduction
0e49% 617 (62.6)
50e99% 291 (29.5)
Occlusion 78 (7.9)
Prior ipsilateral events
Ipsilateral carotid territory symptoms 65 (6.6)
Ipsilateral infarct on CT MRI scan 121 (12.3)
ACST-2 Collaborative Group 513CAS) could both be detected at p < .001 with 80% prob-
ability (i.e. with 80% statistical power), or at 2p < .05 with
95% power. The exact magnitude of any effect is currently
not known, hence the need for the trial, but, taking into
account existing information from other trials of CAS versus
CEA,3 effects of this size might be realistic, meaningful, and
worthwhile. Even smaller effects could be of substantial
interest, but might require much larger numbers to be
studied.
All patients are followed up (unless they choose to
withdraw) whether the trial procedure is carried out or
not, since the main trial analyses will be on an intention-
to-treat basis. By the end of the recruitment period, data
will be available to consider the periprocedural outcomes;
in addition, it is anticipated that at least 2 years’ follow-up
on average will also be available. Analyses will then be
possible of the early effects of CEA versus CAS on the
annual incidence of stroke type and severity. Continued
follow-up will allow more powerful analyses of these
longer-term outcomes. In this paper, the early outcomes
are blinded, and the DMC does not consider that there is
any reason to stop the trial. These results represent a
“pilot” study defining the types of patients randomized,
the varieties of devices and techniques used, and the early
risks of intervention. To understand the longer-term stroke
risks after both interventions we will need to have a
minimum of 5 years’ follow-up on several thousand
patients.
RESULTS
Baseline characteristics
Between February 2008 and September 2012, ACST-2
collaborators working in 68 centres across 23 countries
randomized 986 patients to either CEA (493) or CAS (493).
Baseline characteristics for the whole study population are
shown in Table 1 (and, due to a minimization algorithm,
both randomized groups are well matched for all
measured baseline variables and, due to the size of this
study, should be balanced for unmeasured variables as
well). Males predominated (70%) and the median age of
the current study population is 71 years. Around one-third
of participants had a past history of coronary artery dis-
ease (37%) or diabetes (30%), but renal impairment (11%)
and atrial fibrillation (6%) were less common. Significant
hypertension was uncommon (10%) at presentation, and
the use of appropriate cardiovascular risk factor reduction
medications (antiplatelet agents, 83%; blood pressure
lowering agents, 79%; lipid-lowering therapy, 75%) was
good at randomization and improved during follow-up
(Fig. 1).
The majority of patients treated in ACST-2 had an
ipsilateral stenosis >70% (96%). Most had no significant
contralateral carotid disease (63%), but 8% had a
contralateral occlusion. Prior (i.e. >6 months old) ipsi-
lateral events were infrequent (7%) as were prior
ischaemic lesions on pre-intervention cross-sectional im-
aging (12%).Compliance
Because the trial is ongoing, final compliance is not available,
and to date two patients have died before allocated treat-
ment could be performed. For the 691 patients with at least
1-month follow-up (and 6-month Rankin scoring, for any
stroke) the crossover rate from allocated to non-allocated
treatment at 1-month follow-up was 1.4% (11 patients, 4
allocated to CEA had CAS, 7 allocated CAS underwent CEA).
By 1-month follow up 348 patients had CEA and 343 had
CAS. One-month follow-up was pending for a further 67
patients, and 37 patients (4%) had refused or postponed
treatment. The mean time from randomization to treatment
was 24 days (SD 30.7 days). By 28 days after randomization,
68% had undergone treatment.Techniques
Similar numbers of CEAs were performed under general
anaesthesia (56%) and local/regional anaesthesia (44%),
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local anaesthetic (94%). Carotid patching was used in 50%
of patients undergoing CEA and 29% of CEA patients were
shunted. For CAS, eight types of stent were used (46%
tapered), and Wallstent (Boston Scientific Corp., Boston,
MA, USA) was the most commonly used device (Fig. 2).
Cerebral protection devices (CPDs) were used for almost
all CAS (Fig. 3), and eight types of CPD were employed
(78% filters, 20% proximal systems including flow reversal
and flow arrest systems: Fig. 4). The use of dual anti-
platelet agents was more common in the CAS group
(Fig. 5).Figure 4. Type of cerebral protection (CP) devices used.
Blue ¼ number used.Thirty-day major morbidity and mortality
Amongst all 691 randomized participants with at least 30
days’ follow-up, there were two fatal strokes and a further
four non-fatal but disabling strokes (Table 2). Additionally,
14 non-disabling strokes occurred during this period,
yielding a 30-day stroke rate of 2.9%. There was one fatal MI
and three non-fatal MIs within 30 days of the procedure.
Overall, there were seven (1.0%) vascular events during this
early post-intervention period resulting in death or disabling
stroke.
DISCUSSION
The 30-day results of intervention in the first 691 patients in
ACST-2 show that CEA and CAS in the trial have a 1.0%
immediate risk of disabling stroke and death. Longer-term
follow up will be carried out on all patients for at least 5
years, and these findings will be reported in a future
publication.
Stroke is a significant cause of major morbidity and pre-
mature mortality in the developed world, and strokes
caused by carotid artery stenosis are potentially prevent-
able. When faced with a patient with a haemodynamically
significant carotid stenosis (e.g. 70e99%) the treating
clinician has a range of options. Clearly, if they are certain
that the patient should not have any intervention, or that
the patient requires surgery or stenting specifically, then
randomization to a trial is not appropriate. However, if theyFigure 3. Cerebral protection devices. Blue ¼ number used.are uncertain whether any procedure should be performed,
enrolment into a randomized trial comparing intervention
with a no-procedure control may be appropriate; and if
certain that some procedure is required but uncertain as to
whether stenting or surgery is best, then they should
consider randomizing such patients in ACST-2.
In the ACST-1 trial (1993e2003), overall procedural (CEA)
morbidity and mortality was 3%, and disabling stroke and
death occurred in 1.7% patients.1,2 Prior to intervention, as
in ACST-2, most patients (w95%) were on antithrombotic
(antiplatelet or anticoagulant) treatment and many were on
blood pressure and lipid-lowering medicines. In the 5e10
years since ACST-1 completed recruitment, more patients
with known severe asymptomatic stenosis are now on these
treatments and the number of diabetic patients recruited in
ACST-2 has risen to 30%, reflecting the greater prevalence
of diabetes in older populations. High blood pressure
treatment is started when systolic pressure regularly ex-
ceeds 140 mmHg and higher doses of statins are generally
prescribed.Figure 5. Antiplatelet drug use (during procedure). Blue ¼ carotid
endarterectomy (CEA); red ¼ carotid artery stenting (CAS).
Table 2. Major events within 30 days for 691 patients.
Unrefuted stroke within 30 days, by severity of worst such
stroke
Fatal 2
Disabling 4
Non-disabling (excludes TIA) 14
Total 20
Unrefuted MI within 30 days, by outcome
Fatal 1
Non-fatal 3
Total 4
Vascular event within 30 days that (eventually)
caused death, or disabling stroke within
30 days
7 (1.0%)
Any unrefuted stroke, MI or related death within
30 days
24 (3.5%)
Death in 30 d probably unrelated to stroke,
MI or procedure
2
MI ¼ myocardial infarction; TIA ¼ transient ischaemic attack.
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ACST-1 but we have now included the presence of known
renal dysfunction (w10%). As recruitment increases and
follow-up accumulates, we should be able to determine
whether diabetes and renal dysfunction have an adverse
effect on long-term survival when compared with that seen
in ACST-1.
The only completed trial comparing these treatments in
asymptomatic patients is CREST. About half those recruited
(1,182/2,502) had no prior symptoms and this trial used one
stent device and one CPD, both manufactured by Abbott
Medical (Abbott Park, IL, USA). To date (4-year follow-up),
overall treatment outcomes following CAS in CREST are
similar to CEA with an excess of procedure-related non-
disabling strokes following CAS and of MI after CEA.3
Detection of MI in CREST included some non-clinical
events (with troponin rises alone) which differs from the
ACST-2 protocol. In the long-term, however, both trials as
well as SPACE-2 should be able to compare quality of life
and causes of death and disability following CEA and CAS.
ACST-2 intends to compare a wide range of stents and CPDs,
thereby reflecting normal (mostly European) practice.
However, the ACST-2 trial does not compare intervention
with medical treatment alone. This is being carried out in
the SPACE-2 and ECST-2 studies which are ongoing.5,6 In the
longer term, collaboration between all these studies may
help determine which patients benefit more from
intervention.
We have shown that intervention in asymptomatic ca-
rotid stenosis can be achieved with low risks of major
complications, and the 1.0% rate of major periprocedural
morbidity/early mortality compares favourably with earlier
randomized trials and non-randomized registry data. How-
ever, because of the low rates of complications, a very large
randomized trial with several thousand patients directly
comparing early and long-term risks is needed to reliably
demonstrate any difference between these interventions.
The streamlined design of ACST-2, in which only essential
data are collected, enables the trial to fit in well withroutine clinical care and should facilitate recruitment in a
wide variety of countries across Europe and further afield.
Debate will continue about which (if any) patients with an
asymptomatic carotid artery stenosis will benefit from ca-
rotid intervention to prevent a serious stroke. While the
overall risk of stroke can be reduced substantially by anti-
platelet therapy, blood pressure-lowering agents, and lipid-
lowering therapy,7 in patients with established severe ca-
rotid stenosis, there are no prospective data that medical
therapy is effective in reducing stroke risk compared with
revascularization. Moreover, we have previously shown that
both for patients on statins and those not, allocation to ca-
rotid endarterectomy halved their risk of stroke post proce-
dure. So, whilst we recognize that aggressive risk factor
reduction medications can (subject to good compliance)
substantially reduce global cardiovascular risk (including that
of stroke), such risks cannot be completely abolished by long-
term medication alone. Therefore, successful carotid inter-
vention should be considered as a useful adjunct to good
medical therapy, particularly in patients who could reason-
ably be expected to survive for around 10 years.
In conclusion, worldwide during this decade, around 1
million asymptomatic patients will have a carotid proce-
dure, thereby preventing over 60,000 strokes. Presently,
whether such patients are treated with surgery or stenting
is largely decided by the experience, preference, and prej-
udice of the treating clinician, with marked geographical
variation. The minimally invasive nature of carotid stenting
is appealing to the general public, and the popularity of this
approach could well increase with time. The 30-day results
of intervention in the first 691 patients in ACST-2 show that
CEA and CAS in the trial have an immediate risk of 1.0% of
causing disabling stroke and death, and the independent
Data Monitoring Committee report of March 2012 en-
courages further recruitment in ACST-2, a view shared by
the UK National Institute for Health and Clinical Excellence
(NICE).8
We encourage colleagues to join ACST-2 and, by
randomizing several thousand patients, provide uniquely
reliable evidence to help guide the treatment of asymp-
tomatic patients undergoing carotid intervention. The pro-
tocol for gaining approval and for the trial can be accessed
on www.acst.org.uk.
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tient): Dublin (SN Haider, J Harbison, P Madhavan, D
Moore). Israel (9 patients): Haifa (R Beyar, A Hoffman, T
Karram, A Kerner, E Nikolsky, S Nitecki). Italy (211 patients):
Avenllino (G Amatucci, P Vittorio); Bari ( Prof. Frederico, D
Marinazzo, G Regina), Catania (A Giaquinta, F Patti, M Ver-
oux, P Veroux); Milan (L Adobbati, G Bertoni, P Bianchi, R
Casana, L Cireni, L Martello, V Tolva); Modena (L Arcuri, F
Casoni, G Coppi, R Moratto, J Veronesi); Palermo (G Bajardi,
G Savettieri); Pavia (R Corbetta, A Odero, P Quaretti, Z
Thyrion); Perugia (P Cao, V Caso, P DeRango, L Farchioni, G
Parlani); Reggio Emilia (G Malferrari, F Strozzi, N Tusini, E
Vecchiati); Rome (A Biello, L Capoccia, D Menna, A Rita
Rizzo, E Sbarigia, F Speziale, D Toni); San Donato (M Gio-
vanni, G Meola, G Nano, MT Occiuto, S Stegher, D Tealdi);
San Paolo (F Accrocca, C Ambrogi, R Barbazza, G Marcucci);
Sienna (A Cappelli, G De Donato, G Palasciano, D Pieragalli, C
Setacci, F Settaci); Turin (C Labate, E Ferrero, M Ferri, F
Nessi, A Viazzo); Varese (P Castelli, ML Delodovici, M Fer-
rario, G Piffaretti, G Tomei). Japan: Sendai (E Furui, T Inoue,
R Kondo, Y Matsumoto, H Shimizu); Kazakhstan (2 patients):
Almaty (B Aidashova, N Kospanov, R Lyssenko, D Mussaga-
liev). Netherlands ( 27 patients): Utrecht (GJ De Borst, AG
Den Hartog, R Lo, F Moll, R Toorop, HB Van Der Worp, EJ
Vonken). Norway (8 patients): Oslo (S Bakke, K Krohg-Sor-
ensen, M Skjelland). Poland (26 patients): Warsaw ( P
Andziak, S Drelichowski, M Dratwicki, R Gil, W Iwanowski, K
Koncewicz, M Nowicki, J Pniewski, J Rzezak, P Seweryniak);
Medical University Warsaw (P Bialek, Z Biejat, W Czepel, A
ACST-2 Collaborative Group 517Czlonkowska, A Dowzenko, J Jedzrejewska, A Kobayashi, J
Leszezyuski, A Malek, J Polanski, R Proczka, M Skorski, M
Szostek). Serbia (70 patients): Belgrade, Dedinje Cardiovas-
cular Unit (N Aleksic, S Babic, J Kolar, D Radak, D Sagic, S
Tanaskovic); Belgrade, Serbian Clinical Centre (M Colic, L
Davidovic, D Jovanovic, I Koncar); Slovak Republic (6 pa-
tients): Ruzomberok (D Bartko, P Beno, F Rusnak, K Zelenak).
Slovenia (16 patients): Izola (M Gasparini, A Grad, I Kom-
para, Z Milosevic); Maribor (V Flis, J Matela, K Miksic, F
Milotic, B Mrdja, B Stirn, E Tetickovic). Spain (25 patients):
Barcelona (A Chamorro, V Obach, V Riambau, S Roman);
Guadalajara (E Blanco, AY Izquierdo, M Guerra). Sweden
(115 patients): Helsingborg (E Campbell, H Lindgren, J
Nyberg, G Plate, H Parsson, P Qvarfordt); Malmo (S Acosta, K
Bjorses, K Brandt, N Dias, A Gottsater, J Holst, T Krist-
mundsson, T Kuhme, T Kolbel, B Lindblad, M Lindh, M
Malina, T Ohrlander, T Resch, V Rönnle, B Sonesson, M
Warvsten, Z Zdanowski); Stockholm (B Bengt, M Delle, J
Formgren, P Gillgren, L Jarl, TB Kall, P Konrad, N Nyman, C
Skioldebrand, J Steuer, R Takolander). Switzerland (9 pa-
tients): Basel (FJ Ahlhelm, L Bonati, S S Engelter, T Eugster, H
Gensicke, P Lyrer, L Mariani, P Stierli, C Stippich, T Wolff);
United Kingdom (206 patients): Bishop Auckland (A Mehr-
zad, E Brown, B Esisi); Cambridge (N Butler, DJ Day, P Hayes,
N Higgins, E Jumilla, P Martin, J Mitchell, K Varty); Carlisle (A
Birt, P Davies, J George, A Graham, L Jonker, T Joseph, N
Kelsall, C Potts, T Wilson); Durham (P Davey, R Hayman, G.
Tervitt); Hull (A Abdul-Hamiq, J Bryce, I Chetter, D Ettles, R
Lakshminarayan, K Mitchelsonm, C Rhymes, G Robinson, P
Scott, A Vickers); Kent (H Baht, I Balogun, I Burger, L Cowie,
G Gunathilagan, D Hargroves, R Insall, S Jones, H Rudenko, J
Senaratne, G Thomas, A Thomson); Liverpool (P Enevoldson,
H Nahser, I O’Brian, F Torella D Watling, R White); London (A
Clifton, C Eley, N Khanom, J O’Reilly, A Pereira, C Bicknell, N
Cheshire, R Gibbs, M Hamady, A James, M Jenkins, A Lacey,
M Mireskandari, T Sachs, J Wolfe); Luton (D Hardy, F Justin, L
Phiri, L Sekaran, S Sethuraman, L Tate); Manchester (J
Akyea-Mensah, A Chrisopoulou, JV Smyth); Middlesbrough
(I Nichol, A Parry, G Young); Newcastle (M Clarke, M Davis, A
Dixit, A Dyker, G Ford, R Jackson, S Kappadath, D Lambert, T
Lees, S Louw, S Macdonald, N Parr, G Stansby, L Wales, V
Wealleans, L Wilson, M Wyatt, P Dorman, A Hughes, D
Jones, A D Mendelow, H Rodgers); Nottingham (S MacS-
weeney, N McConachie, A Southam, W Sunman); Oxford (D
Briley, C Darby, A Handa, L Hands, W Kuker, K Michael, J
Perkins, U Schulz, D, Smith, R Teal); Preston (M Donnelly, S
D’Souza, A Asehosem Egun, B Gregory, C Kelly, S Punekar, S
Raj, D Seriki, G Thomson); Sheffield (J Beard, T Cleveland, J
Humphreys, A Jenkins, C King, R Lonsdale, R Nair, S Nawaz, F
Okhuoya, D Turner, G Venables); Southend (J Brown, R
Durairajan, P Guyler, P Harman, M Jakeways, C Khuoge, A
Kundu, T Loganathan, D Sinha, V Thompson, S Tysoe); Sun-
derland (Dr Barer, A Brown, S Crawford, P Dunlop, Dr Maj-
mudar, D Mitchell, Dr O’Brien, Dr O’Connell, Dr Scott, S
Vetrivel); Wythenshawe (R Ashleigh, S Butterfield, G
Gamble, J Ghosh, C McCollum, M Welch, S Welsh); United
States of America (1 patient): Toledo (V Kazan, M Nazzal, V
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